A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease

American Journal of Gastroenterology

Volumn 94, Issue 3, 1999, Pages 674-678

  Colombel, Jean Frédéric ^a   Lémann, Marc ^b   Cassagnou, Michel ^b   Bouhnik, Yoram ^b   Duclos, Bernard ^b   Dupas, Jean Louis ^b   Notteghem, Bertrand ^b   Mary, Jean Yves ^b  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; MESALAZINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CROHN DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DETERIORATION; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; TREATMENT OUTCOME;

ADULT; ANTI-INFECTIVE AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CIPROFLOXACIN; CROHN DISEASE; FEMALE; HUMANS; MALE; MESALAMINE;

EID: 0344457371     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(98)00816-8     Document Type: Article

References (35)

1. Sartor RB. Microbial agents in the pathogenesis, differential diagnosis, and complications of inflammatory bowel disease. In: Blaser MJ, Smith PD, Ravdin JI, Greenberg HB, Guerrant RL, eds. Infections of the gastrointestinal tract. New York: Raven Press, 1995:435-58.
2. Van Kruiningen HJ. On the use of antibiotics in Crohn's disease. J Clin Gastroenterol 1995;20:310-6.
3. Spirt MJ. Antibiotics in inflammatory bowel disease: New choices for an old disease. Am J Gastroenterol 1994;89: 974-8.
4. Hooper DC, Wolfson JS. Fluoroquinolones antimicrobial agents. N Engl J Med 1991;324:384-94.
5. Sanders CC, Sanders WE, Georging RV. Overview of preclinical studies with ciprofloxacin. Am J Med 1987;82:2-11.
6. Brumfitt W, Franklin I, Grady D, et al. Changes in the pharmacokinetics of ciprofloxacin and fecal flora during administration of a 7-day course to human volunteers. Antimicrob Agents Chemother 1984;26:757-61.
7. Wise R, Andrews JM, Dent J. A comparison of the pharmacokinetics and tissue penetration of ciprofloxacin (oral and iv) and ofloxacin (oral) administrated to volunteers, and comparison with in vitro activity (abstr S-42-1). In: Proceedings of the 14th International Congress of Chemotherapy, Kyoto, Japan, 1985.
8. Motohiro T, Nashiyama T, Tominaga K, et al. Effect of Bay 09867, a new quinolone antibacterial agent on human fecal flora (abstr 768). In: Proceedings of the 24th International Congress of Antimicrobial Agents and Chemotherapy, Washington, 1984.
9. Murray BE. Impact of fluoroquinolones on the gastrointestinal flora. Rev Infect Dis 1989;11 (suppl 5):S1372-8.
10. Roche Y, Gougerot-Pocidalo MA, Etienne D, et al. Comparative effects of quinolones on human mononuclear leucocyte functions. J Antimicrob Chemother 1987;19:781-90.
11. Wolf JL. Ciprofloxacin may be useful in Crohn's disease. Gastroenterology 1990;98:A212.
12. Turunen U, Färkkilä M, Valtonen V, et al. Longterm outcome of ciprofloxacin treatment in severe perianal or fistulous Crohn's disease. Gastroenterology 1993;104:A793.
13. Peppercorn MA. Is there a role for antibiotics as primary therapy in Crohn's ileitis? J Clin Gastroenterol 1993;17: 235-7.
14. Prantera C, Zannoni F, Scribano ML, et al. An antibiotic regimen for the treatment of active Crohn's disease: A randomized, controlled clinical trial of metronidazole plus ciprofloxacine. Am J Gastroenterol 1996;91:328-32.
15. Rasmussen SN, Lauritsen K, Tage-Jensen U, et al. 5-aminosalicylic acid in the treatment of Crohn's disease: A 16 week double-blind, placebo-controlled, multicentre study with Pentasa. Scand J Gastroenterol 1987;22:877-83.
16. Singleton JW, Hanauer SB, Gitnick JL, et al. Mesalamine capsules for the treatment of active Crohn's disease: Results of a 16 week trial. Gastroenterology 1993;104:1293-301.
17. Singleton JW. Second trial of mesalamine therapy in the treatment of active Crohn's disease. Gastroenterology 1994; 107:632-3 (letter).
18. Hanauer SB. Update on mesalazine for inflammatory bowel disease. In: Modigliani R, ed. Research and clinical forums: IBD and salicylates-3. Kent: Wells Medical, 1998:203-8.
19. Bernades P, Hecketsweiler P, Benozio M, et al. Proposition d'un système de critères pour le diagnostique des entérocolites inflammatoires cryptogénétiques (maladie de Crohn et rectocolite hémorragique). Gastroenterol Clin Biol 1978;2:1047-54.
20. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index. Gastroenterology 1979;77: 829-42.
21. Royer RJ, Pierfitte C, Netter P. Features of tendon disorders with fluoroquinolones. Thérapie 1994;49:75-6.
22. Whitehead J, Stratton I. Group sequential clinical trials with triangular continuation regions. Biometrics 1983;39:227-36.
23. PEST3. Planning and evaluation of sequential test. Version 3, 1993. University of Reading, U.K.: The Pest project, Dept. Applied Statistics.
24. Whitehead J. The design and analysis of sequential clinical trials. Chichester, U.K.: John Wiley & Sons Ltd, 1997.
25. Boirivant M, Leoni M, Tariciotti D, et al. The clinical significance of serum C-reactive protein levels in Crohn's disease. Results of a prospective longitudinal study. J Clin Gastroenterol 1988;10:401-5.
26. Prantera C, Kohn A. Proposed measures of disease activity: How useful are they. In: Prantera C, Korelitz BI, eds. Crohn's disease. New York: Marcel Dekker, Inc, 1996:187-99.
27. Ambrose NS, Johnson M, Burdon DW, et al. Incidence of pathogenic bacteria from mesenteric lymph nodes and ileal serosa during Crohn's disease surgery. Br J Surg 1984;71:623-5.
28. Laffineur G, Lescut D, Vincent P, et al. Translocation bactérienne dans la maladie de Crohn. Gastroenterol Clin Biol 1992;16:777-81.
29. Cartun RW, Van Kruiningen HJ, Pederson CA, et al. An immunocytochemical search for infectious agents in Crohn's disease. Mod Pathol 1993;6:212-9.
30. Van Kruiningen HJ, Colombel JF, Cartun RW, et al. An in depth-study of Crohn's disease in two French families. Gastroenterology 1993;104:351-60.
31. Liu Y, Van Kruiningen HJ, West AB, et al. Immunocytochemical evidence of Listeria, Escherichia cou and Streptococcus antigens in Crohn's disease. Gastroenterology 1995;108: 1396-404.
32. Bergan T, Delin C, Johansen S, et al. Pharmacokinetics of ciprofloxacin and effect of repeated dosage on salivary and fecal microflora. Antimicrob Agents Chemother 1986;29: 298-302.
33. Shah PM, Enzensberger R, Glogau O, et al. Influence of oral ciprofloxacin or ofloxacin on the fecal flora of human volunteers. Am J Med 1987;82(suppl 4A):333-5.
34. Holt HA, Lewis DA, White LO, et al. Effect of oral ciprofloxacin on the faecal flora of healthy volunteers. Eur J Clin Microbiol 1986;5:201-5.
35. Rozenberg-Arska M, Dekker AW, Verhoef J. Ciprofloxacin for selective decontamination of the alimentary tract in patients with acute leukemia during remission induction treatment: The effect on fecal flora. J Infect Dis 1985;152:1: 104-7.